Introduction
The proportion of people older than 60 years within the total population of developed countries is rapidly growing; the control of disorders related to higher age will increasingly become a focus of the entire health system. Human influenza viruses, naturally occurring during pandemics (influenza A) and epidemics (influenza A and B) cause significant excess morbidity and mortality in the elderly 1'2, not only in those with underlying age-related chronic diseases, but also in apparently healthy subjects 3'4. Thus, prevention of influenza virus infections in the aged would substantially contribute to longevity and state of health. However, active immunization with currently available whole virus, split and subunit vaccines has several draw-backs: the effectiveness of these vaccines is dependent upon the continuously occurring antigenic drift or suddenly occurring antigenic shift of the membrane proteins of the influenza viruses, and they usually stimulate a short-life antibody response only. These facts have led to the recommendation to repeat vaccination annually. Moreover, published reports suggest, to various degrees, a limited efficacy of vaccines to protect aged subjects from influenza infection.
In principle, there are three ways to determine the efficacy of a given vaccine in human beings: (1) the experimental trial, (2) the field trial and (3) the immune response study.
1 In experimental trials, pathogenic effects are recorded in a vaccinated and unvaccinated group after challenge with a live pathogen. Experimental trials have been performed in healthy children and young adult volunteers with both wild or attenuated influenza strains (see Refs 5 and 6) . It is evident that such a study design is impossible in aged populations. 2 In field trials, the challenge occurs by exposition of subjects to the natural field pathogen in the environment. Well-known general and methodological problems of field trials with naturally occurring influenza viruses include unpredictability of the time of its occurrence, antigenic differences between the vaccine strains and epidemic viruses, possible differences in the exposure rates of groups to be compared, and possible misdiagnoses of cases, if not laboratory-confirmed, because of the broad variety of other respiratory pathogens causing influenza-like symptoms. Special ethical problems arise in the aged. Since the benefits of influenza vaccines have been established in the sixties T, ethical reasons have limited the performance of field trials because of the risk to unvaccinated control subjects. As a consequence, most of the studies dealing with influenza-associated morbidity and mortality of vaccinated and unvaccinated aged populations are retrospective and/or suffer from a variety of serious methodological flaws.
Strassburg et al. 8 1982/83 and found important differences in study populations, vaccines, methodology and, as a consequence, levels of vaccine effectiveness. Despite these. restrictions, they estimated average effectiveness rates for morbidity and mortality, respectively. While reduction of mortality in vaccinated subjects, as compared to unvaccinated controls, was calculated as being 67%, reduction of morbidity was found to be much lower (23%). However, experimental and field trials in young, healthy adults in various epidemiological settings, using various vaccines, have repeatedly revealed much higher rates for reduction of morbidity: 60-90% (for review see Ref. 9) . Although comparison of such values should be made very carefully, it could appear that young subjects are better protected than the aged. Among the factors which may contribute to a possibly impaired protection rate in the aged, a direct, age-related impairment of the immunological response to vaccines is to be discussed. 3 The immune response study determines immunological changes after vaccination (mostly antibody production), which are thought to be associated with protection against the pathogen. The various methodological and ethical problems associated with field trials may be avoided. It is essential, of course, that the affirming variables for assessing the protective properties of the vaccine have been sufficiently established by experimental trials and field observations with regard to natural infection.
It is well known that serum IgG antibody against the viral haemagglutinin (HA) plays a major role in protection against influenza 1°'a1: in high concentrations, it provides resistance to acquisition of infection (total protection). In lower concentrations, it prevents or ameliorates disease after infection in a substantial number of cases (partial protection). Many authors define a quantitative protection threshold, i.e. a pre-exposition titre beyond which it is highly unlikely to acquire an infection or to develop illness. Thus, anti-HA serum antibody is a predictor of protection and a measure of vaccine efficacy, which makes immune response studies a good and practical alternative to field trials.
In the present paper, available studies dealing with the anti-HA serum antibody response in elderly subjects upon immunization with inactivated influenza vaccine, are reviewed in an attempt to obtain insight into the correlation between high age and sero-response. The collected information should stimulate further research which may lead to improved policies for the use of current vaccines in the elderly or to the development of new types of vaccines.
For reasons discussed later we did not apply quantitative methods for literature review to construct statistical summaries and comparisons of studies (meta-analysis 12) but chose a traditional narrative approach (qualitative tally), though realizing its limitations ~3. However, we have attempted to obey the strict criteria for metaanalyses as established by Sachs et al. 14. Biological predictor of protection, vaccines, study design and laboratory tests. As outlined above, the production of serum antibody against viral haemagglutinin was chosen as a predictor and measure of vaccine efficacy. The induction of this antibody is strongly induced, apart from natural infection, by immunization with inactivated (whole virus, split or subunit) vaccines, but less so by experimental live vaccines whose protective effects may predominantly be caused by stimulation of local immunity 17. We did not include papers on these latter vaccines.
Materials and methods

Criteria
Any study design was accepted which included the drawing of two blood specimens, one before and a second after vaccination. Booster immunizations were not included. Any laboratory test detecting antibody against viral haemagglutinin was accepted. Tests dealing with antibodies directed against other viral proteins (neuraminidase, core) or measuring cellular immunity were not included, in view of their unknown association with protection.
Year of performance of the studies. The impure and highly reactogenic influenza vaccines used during the 40s, 50s and 60s were of variable potency. It did not seem appropriate for us to include this early vaccine period in our survey. At the end of the 60s, a new generation of highly purified, hardly reactogenic and potent wholevirus vaccines became available 1s'19, followed by split and subunit vaccines in the 70s. Coincidentally, in 1968 a new epidemiological situation occurred with the pandemic emergence of the influenza A-H3N2 subtype. Therefore, we only included studies performed from 1968 onwards.
of mean titres of post-and prevaccination sera, (2) the protection rate (PR), i.e. the proportion of subjects exceeding a given protection threshold after vaccination, (3) the response rate (RR), i.e. the proportion of subjects who show an at least four-fold titre increase 2°'21 after vaccination.
The quantities corresponding with these parameters were either taken directly from the selected papers, or recalculated from their original data if given, or derived from appropriate tables or figures as presented in the original papers. For calculation of the protection rate, the protection threshold as given by the authors was used, or, if not available in the paper, a titre of 36_4011,22,23 when a standard microtitre haemagglutination inhibition technique had been performed. As outlined later, previous antibody against the vaccine component is a factor strongly influencing the production of new homologous antibody upon vaccination. While the protection rate is based on previously unprotected subjects, it has been attempted, for the two other parameters (MFI and RR), to retrospectively stratify the prevaccination state of the study groups as unprotected (including seronegative and low seropositive subjects) or protected subjects prior to vaccination, and to recalculate the quantities for unprotected subjects only. All recalculations are reported in the Tables.
For statistical analysis, the absolute differences between the seroresponse parameters of aged •and young subjects were recalculated, and, for the protection and response rates, also the significance level (z2-test), and the type-2-error which is the probability of concluding that a difference does not exist, when it does in reality. By lack of original data, the significance level of differences between the MFI-values of aged and young groups could not be recalculated and was taken from the original papers if given.
Criteria for the detection of selection biases in the literature
Several factors may influence the production of antibodies after vaccination: health state of the study subjects, intake of drugs at the time of vaccination, and history of exposition to influenza antigens prior to vaccination. Ignoring these factors introduces substantial biases into a trial. Therefore, we examined the selected papers for addressing and correcting these factors.
Health state and use of drugs. Many acute and chronic illnesses (such as viral infections, malnutrition, renal and bone-marrow diseases etc.) and various drugs (such as analgesics, hormones, antimetabolites etc.) are known to impair the functions of the humoral immune system and should therefore lead to exclusion from immune response trials 24.
Prevaccination antibody. Specific or cross-reacting
antibody against a given influenza strain present in high concentrations before vaccination with this strain, may suppress or impair the production of new antibody. According to this 'law of initial values '25 or 'negative feedback '26, the response to a given vaccine strain is inversely related to the specific prevaccination antibody titre. Possibly, already circulating antibody combines with the vaccine to mask its recognition by immunocompetent cells, or, alternatively, switches off new
Influenza vaccines in the elderly: W.E.P. Beyer et al.
immunoglobulin synthesis by a more central mechanism 26. Therefore, when performing vaccination trials, one should carefully describe the prevaccination state of the study populations and analyse the data for different prevaccination classes, or exclude persons with high prevaccination titres.
History of previous vaccinations. Vaccinations with
heterologous influenza viruses in the past, even if they are no longer serologically detectable at the moment of the ungoing study (i.e. in the absence of prevaccination antibodies) may unpredictably influence the antibody production of the vaccine studied: sometimes a boostereffect is observed, sometimes a suppressive effect 27. Subjects with previous vaccination should therefore be excluded.
Results
Papers to be reviewed, and data on study design
The sources revealed 1805 titles for the combination of the keywords 'influenza' and 'vaccination'. Only 20 papers met all our inclusion criteria. Many more papers dealt with influenza vaccination trials in the elderly but had not included control groups consisting of younger subjects. From the 20 selected papers, three 2s-3° were excluded because the anti-HA-IgG ELISA used did not discriminate between the different vaccine components.
Data of seven studies published in the period 1968-88 are presented in Table 1 in chronological order (years of performance of the trial, or, if this information had not been given, year of publication) 19'31-46. Most of the studies (10) were carried out in the United States of America. Only I0 studies (not shown) gave information about the seasonal relationship of the vaccination trial to natural influenza epidemics. Trials performed during or shortly after epidemics with considerable impact would make it difficult to decide whether titre rises were due to the vaccine or to the natural virus.
The period between collection of the pre-and postvaccination sera was usually 21-42 days (not shown); two studies 41'44 chose a shorter interval (14--15 days) which might be suboptimal, and two other papers 39'43 did not give any information in that respect. As a technique for anti-HA-antibody determination, usually the haemagglutination inhibition test was performed, with the exception of Ref. 33 (neutralization test).
As in many studies bi-or trivalent vaccines had been used, the seroresponse to, in total, 30 vaccine components could be studied separately. When using various vaccine types 34 or various dosages 19'42, the data on seroresponse were pooled, either by the authors themselves or by us, as there was a similar stratification among the study group of aged subjects and control groups. From 1967 onwards, the antigenic contents of commercial vaccines has been estimated by comparison with an international influenza A standard preparation and expressed in chicken cell agglutination (CCA) units (IU, international units Table 2 presents data to characterize the size, age range and prevaccination titres of the studied groups of aged and young subjects. The total numbers of groups varied from 1040 and 1133 up to437 and 20334, for elderly and young groups, respectively. The age distribution for the elderly usually reached from 60-70 up to 101 years of age; the young groups consisted of subjects either of a particular narrow age cohort (children 33, young adults 3z'41) or a very broad age range ( < 65 years). Three studies 31'37'45 did not report any age range. The first one characterized the aged group only by the term 'elderly population', the latter two gave high mean ages (80 years, 71-74 years). Another paper 33 presented an age range also including persons younger than 60 years but the text suggested that those subjects had been few. The elderly populations were usually recruited from old people's homes or geriatric institutions which was apparently reflected by the sex distribution: in all studies which gave data on that point, more female than male subjects had been included (not shown).
For 20 vaccine components, the prevaccination state of aged and young groups could be compared. For 10 strains, the elderly had a higher mean titre prior to vaccination; for four strains these values were equivocal, and in six instances the younger groups showed higher mean titres than the elderly. Table 3 shows the results of the serological tests performed with pre-and postvaccination sera, and some basic statistical calculations.
Serological results and statistical calculations
MFI-values for aged and young groups were present in all but one paper; transformed to a logarithmic scale, the MFI varied in a wide range between 0.2-1.4 for aged and 0.2-1.6 for young groups. For 15 of the 30 vaccine components, the authors themselves had given the significance level of the between-group differences for the MFI-values, which in none of these 15 cases was smaller than 5%. The significance level for the remaining papers could not be recalculated by us because of missing raw data in the papers.
The protection and response rates were also heterogenous, reaching from 16 to 93% for aged, and from 21 to 100% for control groups. Between-group differences of protection rates could be calculated for 12 vaccine components, and of response rates for 16 vaccine components. Differences were only small for six protection rates and seven response rates and were not significant on a 5% level, but they had a high type-2-error (51-97%). In these cases, interpretation is difficult as it is not possible to decide whether (1) there really were no differences between age groups or, (2) there were differences, however, the studies were too insensitive (too small sample sizes) to detect these. There were also significant between-group differences, 6 for the protection rate and 9 for the response rate, associated with a low (< 1-5%, 8 cases) or intermediate (1642%, 6 cases) type-2-error. For some vaccine components, a more favourable immune response for the young groups was revealed (significantly negative differences: 2 for PR and 8 for RR). However, also contrary results could be found (significantly positive differences: 4 for PR and 1 for RR).
Thus, a heterogeneous picture could be obtained, with more insignificant and significant results in favour of young subjects, which suggests a slight tendency.
An attempt to combine the pattern of MFI, PR and RR per vaccine component to obtain a tendency per paper is shown in the last column of Table 3 . Where the absolute differences of all given seroresponse measures had the same sign, this sign was used to indicate a tendency (either '-' for a better immune response of younger groups, or '+' for the alternative case). Where one of the given seroresponse measures was significant on the 5% level, the sign was doubled (either '--' or '+ +'). Where the different seroresponse measures showed insignificant differences with different signs, this was expressed as '0' (no tendency detected). Table 5 addresses three important criteria for group composition which should have been obeyed by the papers: absence of illness and drugs influencing the immune system, no previous influenza vaccinations, and stratification for or exclusion of protective prevaccination titres (or presentation of data in a way that this would be possible in retrospect). The documentation of these data was very incomplete in virtually all papers. In six cases it was stated, at least, that the study populations were clinically healthy. Two other papers reported that it dealt in part with 'chronically ill' subjects which did not lead to their exclusion. Another paper 4s included children and young adults with cystic fibrosis as a control group. Only eight studies stated that the vaccinees, in the course of the study, had not used drugs influencing the immune system. Four papers reported that some of the participants had received other influenza vaccinations in previous years which, however, did not lead to o_ < Table 3 Serological results of 17 selected papers, and basic statistical calculations h~ ¢b aBasic statistics include the absolute difference between the seroresponse measures of aged and young groups (Diff), the significance level o~ that difference (Sign, %) and, for PR and RR, the type-2-error (T2, %) bDenominator for calculation of MFI, PR, and RR, respectively CTendency to detect differences in seroresponse between aged and young study groups. --, seroresponse measures higher for young group (---, including significant differences); +, seroresponse measures higher for aged group (+ +, including significant differences); 0, no tendency dNot significant on the 5%-level (ns) eData not given (NG) tComment on calculation of the presented data. See appendix Table 4 Tendency of 17 selected papers to detect differences between aged and young study groups, subdivided for types and subtypes of 30 vaccine strains Type/sub~pe  of vaccine strain  ---0  +  + +   A-H1N1  3  2  1  1  A-H2N2  2  A-H3N2  3  5  3  1  3  B  2  2  2   TotaP  10  9  5  2  4 --, seroresponse variables higher for young group (--, including significant differences); +, seroresponse variables higher for aged group (+ +, including significant differences); 0, no tendency bNumber of vaccine strains exclusion of those subjects. Only one paper dealt expressis verbis with previously unvaccinated subjects. Thus, of the 17 controlled studies, none was free of any bias and 16 failed to address two or three criteria.
Selection biases and combinability of serological results
Tendency a
As the papers revealed a substantial heterogeneity in view of group composition and distribution of main biases which could not be corrected for, it did not appear to be possible to combine or pool the data on serological response (Table 3 ) in the sense of metaanalysis techniques.
Discussion
Influenza viruses are a major cause of mortality and serious morbidity in the elderly. Therefore, recommendations for the use of influenza vaccines have been given in several countries. Is vaccination really effective in this age-group? It is widely believed that, in the elderly, the ability to produce a sufficient amount of antibody after administration of bacterial and viral vaccines, is decreased, alongside with other age-related changes of the entire immune system. Early support for this impression came from the classical study of Sabin et al. 48 describing a lower immune response in aged people to Japanese B encephalitis virus vaccine, as compared to children. This paper has been cited frequently, but the observations of Sabin are based on 20 children and 20 aged individuals only, with a different history of previous expositions to the pathogen. Other support comes from field trials measuring the protection acquired by vaccination, against the naturally occurring pathogens (usually influenza viruses and Streptococcus pneumoniae), often suggesting a lower vaccine effectiveness in the elderly as compared to younger subjects. However, such studies usually struggle with methodological flaws 8'49.
Only a few studies have been published which compare the seroresponse of different age groups to vaccines other than influenza. Results, as a working paper of the World Health Organization pointed out, are 'still incomplete and are often contradictory '15. Ammann et al. 5° in testing a bivalent Streptococcus pneumoniae vaccine, found lower absolute antibody titres but a still sufficient protection rate, in a group of 66 elderly persons, as compared to 20 young adults. Musher et al. 51 described 10 healthy young adults and five aged patients with chronic pulmonary disease after polyvalent Streptococcus pneumoniae vaccination and saw no significant differences in absolute postvaccination antibody titres, but a lower Influenza vaccines in the elderly: W.E.P. Beyer et al.
opsonizing activity, in the sera of the elderly. Other papers on Streptococcus pneumoniae vaccination not including young control groups, report satisfying antibody development in the aged 52-57. Solomonova and Vizev 5a detected a slightly delayed antibody production after vaccination with tetanus toxoid in aged subjects as compared to subjects aged 40-60 years. The difference, however, was not significant. In 70 non-dialysed elderly individuals, Denis et al. 59 found a profoundly impaired seroresponse to hepatitis B vaccine.
In an attempt to reveal, from the recent literature, the association between high age and the ability to produce specific antibodies after influenza vaccination, we could not detect a clear answer, but a tendency only: for 10 out of 30 single vaccine components, statistical calculations suggest a lower response of the elderly, as compared to younger control subjects. Another 9 cases support this tendency but show insignificant differences between age groups only. On the other hand, some contradictory results exist as well (elderly more favourable than young in 4 cases).
We showed that virtually all studies reviewed by us insufficiently controlled two major groups of biases: differences in health state and differences in previous exposure to influenza antigens. The general direction of these selection biases is such that failure to control these leads to an underestimation of the response of the elderly: in this age group, the prevalence of disease and drug use influencing the immune system, the chance of previous vaccinations, and the mean titres of prevaccination antibody, are generally higher. Neglecting these factors during the selection of the study subjects has introduced a considerable heterogeneity in the study groups of the papers reviewed and has also seriously affected the validity of the described results which may then give an idea about the overall condition of the group studied, but cannot lead to conclusions concerning fundamental age-related changes in the immune system. Although we saw a tendency supporting a decreased seroresponse in Table 7) the elderly, the high prevalence of biases does not justify any generalization. The association between high age and responsiveness to influenza vaccines, if any, has not yet been established. In this paper, we have used basic statistical methods analogous to another review on influenza vaccinology: Gross et al. 6° reviewed 12 studies on the effects of cancer chemotherapy on the seroresponse to influenza vaccines and found that in eight papers a significantly lower antibody development in subjects on treatment, as compared to untreated control subjects, had been established. Moreover, they detected a high type-2-error in the remaining four studies which could not find any significant effects of chemotherapy which was probably due to insensitivity rather than to the absence of such differences. In contrast to the definite results of Gross et al., our results are more heterogeneous, even taking into account that many papers in our review had also a high type-2-error. The main distinction between the two reviews appears to be the fact that in the studies included by Gross et al., there was usually no major difference in age distribution, and, as a consequence, the two major groups of biases, differences in health state and in previous exposure to influenza antigens, were avoided.
Based on the considerations in the section Materials and methods of this review, we suggest admission criteria for future immune response studies in the elderly as described 'in Table 6 . To define the health state of vaccinees, general criteria such as 'apparently healthy' or 'without overt diseases' are insufficient to exclude underlying disease, as pointed out by Ligthart et al. 24 . Therefore the strict 'Senieur Protocol: Admission criteria for immunogerontological studies in man' should be used as it includes clearly defined anamnestic and clinical information, laboratory data and drug interference. Subjects previously immunized with any hetero-or homologous influenza vaccines, and subjects who do not clearly remember, are to be excluded. Subjects with high/protective serum antibody prior to vaccination, specifically directed against the vaccine component, are to be excluded. The exclusion threshold may be dependent on the antibody detection method used.
In contrast to the three criteria mentioned above which can be controlled by an appropriate study design, the age-related exposition to different influenza A subtypes is a factor which cannot be controlled. However, it strongly influences the immune response to vaccination even dozens of years later. Table 7 shows the natural occurrence of haemagglutinin subtypes from 1889 onwards, as has been established by seroepidemiological studies and, from 1933 onwards, by direct isolations in man 61. In particular, the first influenza A infection during We believe that the use of strict selection and stratification criteria is mandatory if one wishes to study ageing per se. More knowledge of the latter is needed to develop appropriate strategies to protect elderly who do suffer from diseases and who have an increased risk of acquiring complications during or after influenza infection.
